Merck (NYSE: MRK)
Merck Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Merck Company Info
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
News & Analysis
Should Investors Buy Merck Stock After These Huge Risks?
Stock Market Crash: 3 High-Yielding Dividend Stocks Near Their 52-Week Lows to Buy Right Now
Pharmaceutical tariffs: Which countries does the U.S. import the most from?
The U.S. has significant pharmaceutical trade deficits with Ireland, Switzerland, and Singapore.
The Largest Healthcare Companies by Market Cap in May 2025
Eli Lilly, Johnson & Johnson, and UnitedHealth Group command the healthcare sector.
2 Beaten-Down Stocks to Buy and Hold for a Decade
Which Dow Jones Stock Is Cheaper, Amgen or Merck?
Is Merck Stock a Bargain Buy?
Why Pharma and Biotech Stocks Got Thrashed on Tuesday
Valuation
Podcast Episodes
News! News! News! Here's What's Happened in Healthcare Last Week
From a big-time patent settlement between Merck & Co. and Bristol-Myers Squibb, to Johnson & Johnson's earnings, to Aetna and Humana's $37 billion merger bust, we dive into the details behind last week's biggest healthcare stories.
Patent Palooza: One Patent Battle in Hep C, And Another Patent Brawl Brewing On Capitol Hill
Merck, Gilead Sciences, and Ionis get a verdict in their patent suit, and Congress calls for a patent review of Medivation's Xtandi.
Earnings Transcripts
Merck (MRK) Q4 2024 Earnings Call Transcript
MRK earnings call for the period ending December 31, 2024.
Merck (MRK) Q3 2024 Earnings Call Transcript
MRK earnings call for the period ending September 30, 2024.
Merck (MRK) Q2 2024 Earnings Call Transcript
MRK earnings call for the period ending June 30, 2024.
Merck (MRK) Q1 2024 Earnings Call Transcript
MRK earnings call for the period ending March 31, 2024.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.